Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Predicting the Long-Term Efficacy of Ifnα in JAK2 V617F and Calr -Mutated MPN Patients

Blood (2019) 134 (Supplement_1): 4196.

https://doi.org/10.1182/blood-2019-127903

Published: 2019

Journal Articles

Differential Impact of Interferon Alpha on JAK2 V617F and Calr Mutated Hematopoietic Stem and Progenitor Cells in Classical MPN

Matthieu Mosca, PhDstudent, Lamia Lamrani, PhD, Christophe Marzac, MD, Amandine Tisserand, Valérie Edmond, PhD, Tracy Dagher, PhDstudent, Mira El-Khoury, PhD, Caroline Marty, PhD, Hugo Campario, PharmD, Nicole Casadevall, MD, Eric Solary, MD PhD, Hana Raslova, PhD, Bruno Cassinat, PharmD, PhD, Stefan N Constantinescu, MD, Jean-Jacques Kiladjian, MD PhD, Francois Girodon, MD PhD, Jean-Luc Villeval, PhD, William Vainchenker, MD PhD, Isabelle Plo, PhD

Blood (2018) 132 (Supplement 1): 4333.

https://doi.org/10.1182/blood-2018-99-114744

Published: 2018

Journal Articles

Rare Type 1-like and Type 2-like Calrecticulin Mutants Induce Similar Myeloproliferative Neoplasms Than Type 1 and Type 2 Mutants in Mice

Katte Rao Toppaldoddi, Maira da Costa Cacemiro, Olivier Bluteau, PhD, Amélie Pioch, Barbara Panneau-Schmaltz, PhD, Delphine Muller, Nicole Casadevall, MD, Hana Raslova, PhD, Stefan N. Constantinescu, MD PhD, Isabelle Plo, William Vainchenker, MD PhD, Caroline Marty, PhD

Blood (2017) 130 (Supplement 1): 1665.

https://doi.org/10.1182/blood.V130.Suppl_1.1665.1665

Published: 2017

Journal Articles

Calreticulin Mutants Induce an Early Clonal Dominance and a Megakaryocytic Phenotype through the Activation of MPL/JAK2 Pathway in Human Primary Cells

Mira EL Khoury, Gaelle Vertenoeil, Caroline Marty, Christophe Marzac, Matthieu Mosca, Christian Pecquet, PhD, Fabrizia Favale, Robert Kralovics, Najet Debili, Nicole Casadevall, MD, Hana Raslova, PhD, Stefan N. Constantinescu, MD PhD, Isabelle Plo, William Vainchenker, MD PhD

Blood (2016) 128 (22): 1959.

https://doi.org/10.1182/blood.V128.22.1959.1959

Published: 2016

Journal Articles

New Insights into Mechanisms of Erythropoietin Receptor Mutations in Primary Familial and Congenital Polycythemia

Florence Pasquier, MD PhD, Caroline Marty, PhD, Frédérique Verdier, PhD, Sarah Grosjean, MBiol, Claude Préhu, MD, Stefan N. Constantinescu, MD PhD, Hana Raslova, PhD, Nicole Casadevall, MD, William Vainchenker, MD PhD, Christine Bellanné-Chantelot, PharmD, PhD, Isabelle Plo, PhD

Blood (2016) 128 (22): 631.

https://doi.org/10.1182/blood.V128.22.631.631

Published: 2016

Journal Articles

Differential Association of Calreticulin Type 1 and Type 2 Mutations with Myelofibrosis and Essential Thrombocytemia: Relevance for Disease Evolution

Blood (2014) 124 (21): 1823.

https://doi.org/10.1182/blood.V124.21.1823.1823

Published: 2014

Journal Articles

Use Of 46/1 Haplotype Permits To Follow JAK2 V617F Clonal Architecture In PV Patients: Clonal Evolution and Impact Of IFNα Treatment

Salma Hasan, PhD student, Bruno Cassinat, PharmD, PhD, Jean-Pierre Le Couédic, Fabrizia Favale, Barbara Monte-Mor, Catherine Lacout, Eric Solary, MD, PhD, Jean-Luc Villeval, PhD, Nicole Casadevall, MD, Jean-Jacques Kiladjian, MD, PhD, William Vainchenker, MD, PhD, Isabelle Plo, Ph.D

Blood (2013) 122 (21): 4109.

https://doi.org/10.1182/blood.V122.21.4109.4109

Published: 2013

Journal Articles

46/1 Haplotype Permits to Follow JAK2 Homologous Recombination: Modeling JAK2 V617F clonal Architecture in PV Patients

Salma Hasan, PhD Student, Jean Pierre Le Couedic, Fabrizia Favale, Barbara Monte-Mor, Catherine Lacout, Nicole Casadevall, MD, Eric Solary, Jean-Luc Villeval, PhD, Isabelle Plo, Ph.D, William Vainchenker, MD, PhD

Blood (2012) 120 (21): 1757.

https://doi.org/10.1182/blood.V120.21.1757.1757

Published: 2012

Journal Articles

Clinical Implications for Patients with Low JAK2V617F Allele Burden

Marguerite Vignon, Dorota Jeziorowska, Pierre Hirsch, MD, Ollivier Legrand, MD, PhD, Nicole Casadevall, MD, Francois Delhommeau, PharmD, PHD, Christophe Marzac, MD

Blood (2012) 120 (21): 1745.

https://doi.org/10.1182/blood.V120.21.1745.1745

Published: 2012

Journal Articles

Inhibition of TET2 Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine Disturbs Myelopoiesis and Granulo-Monocytic Differentiation.

Elodie Pronier, Carole Almire, Barbara da Costa Reis Monte Mor, Audrey Simon, Aline Massé, Hayat Mokrani, Nicole Casadevall, MD, Jean-Luc Ravanat, Eric Solary, William Vainchenker, MD, PhD, Isabelle Plo, Francois Delhommeau, PharmD, PhD

Blood (2010) 116 (21): 1584.

https://doi.org/10.1182/blood.V116.21.1584.1584

Published: 2010

Journal Articles

Erythrocytapheresis in Sickle Cell Disease Lead to An Elective Reduction of Erythrocytes-Derived Blood Microparticles

Emna Mahfoudhi, Yann Lecluse, Françoise Driss, Claire Flaujac, Nicole Casadevall, MD, Salem Abbes, Garçon Loïc

Blood (2010) 116 (21): 2657.

https://doi.org/10.1182/blood.V116.21.2657.2657

Published: 2010

Journal Articles

TET2 Is a Novel Tumor Suppressor Gene Inactivated in Myeloproliferative Neoplasms: Identification of a Pre-JAK2 V617F Event

Francois Delhommeau, Sabrina Dupont, Chloe James, MD, PhD, Aline Masse, Jean Pierre le Couedic, Veronique Della Valle, Antonio Alberdi, Philippe Dessen, Michaela Fontenay, Nicole Casadevall, MD, Jean Soulier, MD, PhD, Olivier Bernard, William Vainchenker

Blood (2008) 112 (11): lba-3.

https://doi.org/10.1182/blood.V112.11.lba-3.lba-3

Published: 2008

Journal Articles

Role of JAK 2 Mutation Detection in Budd-Chiari Syndrome (BCS) and Portal Vein Thrombosis (PVT) Associated to MPD.

Jean-Jacques Kiladjian, MD, Francisco Cervantes, MD,PhD, Frank W.G. Leebeek, MD,PhD, Sylvie Chevret, MD,PhD, Dominique Cazals-Hatem, MD, Aurélie Plessier, MD, Christophe Marzac, MD, Bruno Cassinat, MD, Sebastian Raffa, MD, Juan Carlos Garcia-Pagan, MD,PhD, Sarwa Darwish Murad, MD,MSc, Harry L.A. Janssen, MD,PhD, Dominique Valla, MD,PhD, Nicole Casadevall, MD,PhD, Pierre Fenaux, MD,PhD

Blood (2006) 108 (11): 377.

https://doi.org/10.1182/blood.V108.11.377.377

Published: 2006

Journal Articles

JAK2 V617F in 3 Patients with Venous Thromboembolism (VTE) Followed during a Long Period of Time.

Jacqueline Conard, PhD, Christophe Marzac, MD, Fabrice Juin, PhD, Marie-Helene Horellou, MD, Ors’Antone Calendini, MD, Nicole Casadevall, MD

Blood (2006) 108 (11): 4092.

https://doi.org/10.1182/blood.V108.11.4092.4092

Published: 2006

Journal Articles

Prognosis Value of Flt3 Internal Tandem Duplication and P-Glycoprotein Functionality, in 171 AML.

Christophe Marzac, MD, Irene Teyssandier, MD, Jean Yves Perrot, MD, Anne Marie Faussat, MD, Ruoping Tang, PhD, Nicole Casadevall, MD, PhD, Jean Pierre Marie, MD, PhD, Ollivier Legrand, MD, PhD

Blood (2005) 106 (11): 2375.

https://doi.org/10.1182/blood.V106.11.2375.2375

Published: 2005

Journal Articles

Phenotypic Description of Familial Chronic Myeloproliferative Disorders.

Albert Najman, MD, Isabelle Chaumarel, MD, Christine Bellann-Chantelot, PharmD., Ph.D., Veronique Barbu, MD,PhD, Myriam Labopin, MD,PhD, Jean D. Rain, MD,PhD, Nicole Casadevall, MD, Bruno Varet, MD, Francis Bauters, MD, Gilles Thomas, MD,PhD

Blood (2004) 104 (11): 658.

https://doi.org/10.1182/blood.V104.11.658.658

Published: 2004

NARROW

Predicting the Long-Term Efficacy of Ifnα in JAK2 V617F and Calr -Mutated MPN Patients

Differential Impact of Interferon Alpha on JAK2 V617F and Calr Mutated Hematopoietic Stem and Progenitor Cells in Classical MPN

Rare Type 1-like and Type 2-like Calrecticulin Mutants Induce Similar Myeloproliferative Neoplasms Than Type 1 and Type 2 Mutants in Mice

Calreticulin Mutants Induce an Early Clonal Dominance and a Megakaryocytic Phenotype through the Activation of MPL/JAK2 Pathway in Human Primary Cells

New Insights into Mechanisms of Erythropoietin Receptor Mutations in Primary Familial and Congenital Polycythemia

Differential Association of Calreticulin Type 1 and Type 2 Mutations with Myelofibrosis and Essential Thrombocytemia: Relevance for Disease Evolution

Use Of 46/1 Haplotype Permits To Follow JAK2 V617F Clonal Architecture In PV Patients: Clonal Evolution and Impact Of IFNα Treatment

46/1 Haplotype Permits to Follow JAK2 Homologous Recombination: Modeling JAK2 V617F clonal Architecture in PV Patients

Clinical Implications for Patients with Low JAK2V617F Allele Burden

Inhibition of TET2 Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine Disturbs Myelopoiesis and Granulo-Monocytic Differentiation.

Erythrocytapheresis in Sickle Cell Disease Lead to An Elective Reduction of Erythrocytes-Derived Blood Microparticles

TET2 Is a Novel Tumor Suppressor Gene Inactivated in Myeloproliferative Neoplasms: Identification of a Pre-JAK2 V617F Event

Role of JAK 2 Mutation Detection in Budd-Chiari Syndrome (BCS) and Portal Vein Thrombosis (PVT) Associated to MPD.

JAK2 V617F in 3 Patients with Venous Thromboembolism (VTE) Followed during a Long Period of Time.

Prognosis Value of Flt3 Internal Tandem Duplication and P-Glycoprotein Functionality, in 171 AML.

Phenotypic Description of Familial Chronic Myeloproliferative Disorders.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only